Holen Sie sich die Stockscreener-App
2.75
4.96%
0.13
Handel nachbörslich:
2.70
-0.05
-1.82%
Schlusskurs vom Vortag:
$2.62
Offen:
$2.64
24-Stunden-Volumen:
1.67M
Relative Volume:
0.95
Marktkapitalisierung:
$313.92M
Einnahmen:
$618.00K
Nettoeinkommen (Verlust:
$-111.65M
KGV:
-1.9699
EPS:
-1.396
Netto-Cashflow:
$-107.53M
1W Leistung:
+4.96%
1M Leistung:
-12.97%
6M Leistung:
-34.05%
1J Leistung:
-19.83%
1-Tages-Spanne:
$2.55
$2.775
1-Wochen-Bereich:
$2.44
$2.775
52-Wochen-Spanne:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Firmenname
Perspective Therapeutics Inc
Sektor
Branche
Telefon
509-375-1202
Adresse
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
2.75 | 287.66M | 618.00K | -111.65M | -107.53M | -1.396 |
ABT
Abbott Laboratories
|
98.83 | 175.27B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
86.29 | 113.38B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
275.39 | 104.47B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.65 | 63.65B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.32 | 49.74B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-11-24 | Fortgesetzt | Truist | Buy |
| 2025-10-10 | Eingeleitet | BTIG Research | Buy |
| 2025-03-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-11-25 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-01 | Eingeleitet | Wedbush | Outperform |
| 2024-09-25 | Eingeleitet | Truist | Buy |
| 2024-07-25 | Eingeleitet | BofA Securities | Buy |
| 2024-05-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Perspective Therapeutics Inc Aktie (CATX) Neueste Nachrichten
Form 13D/A Perspective Therapeutics For: 26 September By Investing.com - Investing.com Nigeria
Perspective Therapeutics Inc (CATX) Stock Price Target & Forecast - TradingKey
After selling nearly 1.4 million shares in one day, a Perspective Therapeutics (CATX) holder still has a stake. - Stock Titan
Perspective Therapeutics Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SharesEPS Consistency Score - siam.in
Perspective Therapeutics (CATX) Climbs 3.13% to $2.97, Nearing Resistance at $3.12Mutual Fund Flow - dars.gov.et
Perspective Therapeutics, Inc.(NYSEAM:CATX) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
This $3 Biotech Could Be Worth $11.45, Analyst Says - benzinga.com
William Blair initiates Perspective Therapeutics stock with outperform rating - Investing.com
William Blair Initiates Perspective Therapeutics With Outperform Rating - marketscreener.com
William Blair initiates Perspective Therapeutics stock with outperform rating By Investing.com - Investing.com Canada
William Blair Initiates Perspective Therapeutics(CATX.US) With Buy Rating - Moomoo
Perspective Therapeutics Inc (CATX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BMO Capital Maintains Perspective Therapeutics(CATX.US) With Buy Rating, Maintains Target Price $11 - Moomoo
Perspective Therapeutics partners with Merck on cancer trial By Investing.com - Investing.com South Africa
Perspective Therapeutics partners with Merck on cancer trial - Investing.com
Form 8K Perspective Therapeutics Inc For: 14 September By Investing.com - Investing.com UK
Merck joins Perspective Therapeutics (NYSE: CATX) to test Keytruda combo in Phase 1/2a cancer trial - Stock Titan
Perspective Therapeutics Announces Clinical Trial Collaboration with Merck to Evaluate PSV359 in Combination with Keytruda in Advanced FAP-α-Positive Solid Tumors - quiverquant.com
Perspective Therapeutics Enters Cancer Clinical Trial Collaboration With Merck; Shares Up Pre-Bell - marketscreener.com
Perspective Therapeutics to present NET therapy trial data - grafa.com
Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the 38th EORTC-NCI-AACR Symposium 2026 - Yahoo Finance
Perspective Therapeutics (CATX) Insider Sale: 10% Owner Lantheus Alpha Therapy, LLC Sells 247,932 Shares - GuruFocus
Perspective Therapeutics updates corporate presentation highlighting 212Pb pipeline, $45B addressable market - TradingView
Perspective Therapeutics (CATX) highlights 3 cancer drug programs - Stock Titan
Perspective Therapeutics (CATX) holder sells stock near $3.10 - Stock Titan
Lantheus Alpha Therapy Sells 113,914 Perspective Therapeutics (AMEX: CATX) Shares at Up to $3.14 Per Share - Kalkine Media
Lantheus Group Reduces Stake in Perspective Therapeutics (AMEX: CATX) to 10% Amid Activist 13D Filing - Kalkine Media
Lantheus Holdings (NASDAQ: LNTH) 10% Stakeholder Alpha Therapy Sells 42,129 Shares at $3.11 Each - Kalkine Media
Perspective Therapeutics (CATX) Insider Sell: 10% Owner Lantheus Alpha Therapy, LLC Disposes of 42,129 Shares - GuruFocus
Lantheus Holdings (NASDAQ: LNTH) Disposes of 35,769 Perspective Therapeutics Shares at $3.12 Each - Kalkine Media
Perspective Therapeutics (CATX) backer trims stake but keeps 11.5M shares - Stock Titan
10% owner of Perspective Therapeutics (NYSE: CATX) sells 113,914 shares over two days - Stock Titan
Perspective Therapeutics (CATX) backer Lantheus now owns 10% after share sales - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 35,769 Shares - GuruFocus
Perspective Therapeutics (CATX) holder sells 35K shares, still owns 11.6M - Stock Titan
Perspective Therapeutics Inc (CATX) Insider Sell: 10% Owner Holdings, Lantheus Disposes of 78,145 Shares - GuruFocus
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock By Investing.com - Investing.com Nigeria
Lantheus Holdings sells $245,609 in Perspective Therapeutics stock - Investing.com
CATX Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.22 Beats EstimatesShort-Term Outlook - dars.gov.et
Perspective Therapeutics: 'Strong Buy' On Bamzireotide Navoxetan Reinforced Data And Phase 3 Plans - Seeking Alpha
Perspective Therapeutics (CATX) Slides 3.19% as $3.03 Support Comes into FocusMomentum Surge Alerts - vinanet.vn
Perspective (CATX) Quarterly Results: Reported EPS Tops Expectations at the Close; Post-Earnings: The Market Price Declines 3.03% for the Current SessionProfit Inflection Point - vinanet.vn
Perspective Therapeutics (CATX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Eastern Progress
BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy" - MarketBeat
Perspective (CATX) Range: Posts a 8.41% Gain to $3.48 for the Current Session; Chart View - vinanet.vn
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11 - Bitget
Perspective Therapeutics Market Sentiment - Benzinga France
CATX Initiated by BMO Capital -- Rating Set to Outperform - GuruFocus
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital - Moomoo
BMO initiates Perspective Therapeutics stock at Outperform, $11 target By Investing.com - Investing.com South Africa
BMO initiates Perspective Therapeutics stock at Outperform, $11 target - Investing.com
Finanzdaten der Perspective Therapeutics Inc-Aktie (CATX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.75%
Kapitalisierung:
|
Volumen (24h):